Electra Therapeutics to Present Clinical Data for ELA026 in the Treatment of sHLH in an Oral Session at the 2024 Annual Meeting of the Histiocyte Society
Data from the Phase 1b Study of ELA026 in secondary hemophagocytic lymphohistiocytosis (sHLH) highlights preliminary efficacy in patients with the poorest prognosis, those with malignancy-associated HLH SOUTH SAN FRANCISCO, CA, October 29, 2024 – Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced today […]
